Listen Live
WRNB HD2 Featured Video
CLOSE

Two California researchers have developed a procedure using growth factors from a woman’s own blood, which appears to have markedly improved a woman’s sexual response.

The researchers, Drs. Samuel Wood and Charles Runels , are encouraged by preliminary results from this simple office procedure that involves the injection of the blood platelet-derived growth factors (PDGFs) into the upper wall of the vagina and clitoris.

Wood and Runels presented their findings at the annual meeting of the A4M, the largest biomedicine convention in the country.

Wood is a renowned reproductive endocrinologist, stem cell scientist and fertility specialist. Runels is a cosmetic physician, endocrinologist and expert in the treatment of diabetes.

“The most important factor in the success of this procedure is the correct placement of the injections,” Wood said at the conference. “When injected into an area distinct from the traditionally defined ‘G-Spot,’ the response has been surprising, robust and consistent.”

Wood said that he and Runels decided to name the injection site the “O-Spot” and have trademarked the procedure as the “O-Shot” or “Orgasm Shot.”

The doctors said accurately identifying the O-Spot is critical to determining whether a woman is able to achieve a vaginal orgasm, something that is experienced by fewer than 20 percent of women and that 40 percent of all women experience some form of sexual dysfunction during their lifetimes.

Wood and Runels recommended that patients get a complete physical before seeking the O-Shot to rule out any other problems. They said that more than 20 years of use of PDGFs for other health issues indicated that the injections are safe to use and can be administered with nothing more than a local anesthetic and is associated with only minimal discomfort.

The O-Shot, however, has not been approved for general use and Wood and Runels cautioned that the injections should be provided only as part of a clinical research trial.

“We recognize that this data is preliminary and must be confirmed by rigorous scientific research before making it widely available to patients,” Wood said. “We are now initiating a multicenter clinical trial to definitely examine the effectiveness of this procedure.”

The shot costs $1,500, which includes what Wood calls a “comprehensive sexual dysfunction assessment” to screen for other contributing factors, and it’s not covered by insurance, the Florida Sun-Sentinel reported in February.

Wood told The Sun-Sentinel said he is simultaneously conducting a double-blind, placebo-controlled study on the shot’s effectiveness that will be peer-reviewed, even though that is not required and the technique is not subject to approval by the Food and Drug Administration.

“I’m not going to be involved in something that is not actively researched. We want to be really sure about it,” Wood said, adding that one reason the technique is proprietary is to ensure that only those professionals with the proper credentials and training are offering it. “We don’t want someone to take a good procedure and give it a bad name by doing it incorrectly.”

Wood also said that early studies showed that pre-menopausal women had a higher improved response rate than post-menopausal women whose sexual dysfunction may be exacerbated by low estrogen levels and other age-related issues.

Click here for answers to your “Get Well Wednesday” questions.

Move Over Viagra, Make Room for the O-Spot  was originally published on blackamericaweb.com